Gardiquimod diTFA
规格
| Cas Number | 1159840-61-5 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 50 mg/mL (92.35 mM; Need ultrasonic) H2O : 25 mg/mL (46.17 mM; Need ultrasonic) |
| 过滤标签 | Toll-like Receptor (TLR),HIV,Immunology/Inflammation,Anti-infection |
| 储存温度 | 2-8°C储存,干燥 |
| 运输条件 | 冰袋运输 |
| 生化和生理学机理 | Gardiquimod diTFA 是一种咪唑喹啉类似物，是一种 TLR7/8 激动剂。Gardiquimod diTFA 可抑制巨噬细胞和活化的外周血单核细胞（PBMCs）感染 HIV-1。Gardiquimod diTFA 在使用浓度为 0.5 μg/L 时能特异性激活 TLR7。 |
| 英文描述 |
Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10 μM In Vitro Gardiquimod diTFA (6-60 μM ) significantly inhibits cDNA synthesis by HIV-1 reverse transcriptase. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Dendritic cells (DCs) in combination with Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) improves the anti-tumor effects of NK cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male athymic nude mice (Balb-nu/nu, 5 weeks old) (bearing human HepG2 liver carcinoma xenografts)Dosage: 1 mg/kg per mouse Administration: i.p.; daily for 7 days Result: Significantly suppressed the growth of human HepG2 liver carcinoma xenografts. Form:Solid IC50& Target:TLR7 TLR8 HIV-1 |